Metaproterenol Pregnancy and Breastfeeding Warnings

Brand names: Alupent, Metaprel

Medically reviewed by Drugs.com. Last updated on Aug 7, 2025.

Metaproterenol Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

Animal studies showed teratogenicity (including skeletal abnormalities, hydrocephalus, and skull bone separation) at 62 times the maximum recommended human dose (MRHD); embryotoxicity was seen at 31 times the MRHD; oral reproduction studies at 40 mg/kg and 50 mg/kg did not show teratogenicity, embryotoxicity, or fetotoxicity. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Metaproterenol Breastfeeding Warnings

Use is recommended only if the benefit outweighs the risk.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer